Evidence map›Paper›PMID 25114143›Full record

ArticleAntimicrobial agents and chemotherapy2014

Evolution of oseltamivir resistance mutations in Influenza A(H1N1) and A(H3N2) viruses during selection in experimentally infected mice.

Andrés Pizzorno, Yacine Abed, Pier-Luc Plante, Julie Carbonneau, Mariana Baz, Marie-Ève Hamelin, Jacques Corbeil, Guy Boivin

Open access · bronzeAbstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Andrés PizzornoResearch Center in Infectious Diseases of the CHU of Québec and Laval University, Québec City, Quebec, Canada.
Yacine AbedResearch Center in Infectious Diseases of the CHU of Québec and Laval University, Québec City, Quebec, Canada.
Pier-Luc PlanteResearch Center in Infectious Diseases of the CHU of Québec and Laval University, Québec City, Quebec, Canada.
Julie CarbonneauResearch Center in Infectious Diseases of the CHU of Québec and Laval University, Québec City, Quebec, Canada.
Mariana BazResearch Center in Infectious Diseases of the CHU of Québec and Laval University, Québec City, Quebec, Canada.
Marie-Ève HamelinResearch Center in Infectious Diseases of the CHU of Québec and Laval University, Québec City, Quebec, Canada.
Jacques CorbeilResearch Center in Infectious Diseases of the CHU of Québec and Laval University, Québec City, Quebec, Canada.
Guy BoivinResearch Center in Infectious Diseases of the CHU of Québec and Laval University, Québec City, Quebec, Canada guy.boivin@crchul.ulaval.ca.
Université Laval · CA

Funding

Canadian Institutes of Health Research 229733Canadian Institutes of Health Research 230187
6 · The paper itself

Abstract

The evolution of oseltamivir resistance mutations during selection through serial passages in animals is still poorly described. Herein, we assessed the evolution of neuraminidase (NA) and hemagglutinin (HA) genes of influenza A/WSN/33 (H1N1) and A/Victoria/3/75 (H3N2) viruses recovered from the lungs of experimentally infected BALB/c mice receiving suboptimal doses (0.05 and 1 mg/kg of body weight/day) of oseltamivir over two generations. The traditional phenotypic and genotypic methods as well as deep-sequencing analysis were used to characterize the potential selection of mutations and population dynamics of oseltamivir-resistant variants. No oseltamivir-resistant NA or HA changes were detected in the recovered A/WSN/33 viruses. However, we observed a positive selection of the I222T NA substitution in the recovered A/Victoria/3/75 viruses, with a frequency increasing over time and with an oseltamivir concentration from 4% in the initial pretherapy inoculum up to 28% after two lung passages. Although the presence of mixed I222T viral populations in mouse lungs only led to a minimal increase in oseltamivir 50% enzyme-inhibitory concentrations (IC50s) (by a mean of 5.7-fold) compared to that of the baseline virus, the expressed recombinant A/Victoria/3/75 I222T NA protein displayed a 16-fold increase in the oseltamivir IC50 level compared to that of the recombinant wild type (WT). In conclusion, the combination of serial in vivo passages under neuraminidase inhibitor (NAI) pressure and temporal deep-sequencing analysis enabled, for the first time, the identification and selection of the oseltamivir-resistant I222T NA mutation in an influenza H3N2 virus. Additional in vivo selection experiments with other antivirals and drug combinations might provide important information on the evolution of antiviral resistance in influenza viruses.

Indexed as

AnimalsAntiviral AgentsBase SequenceCell LineDogsDrug Resistance, ViralEnzyme InhibitorsEvolution, MolecularHemagglutinins, ViralHigh-Throughput Nucleotide SequencingInfluenza A Virus, H1N1 SubtypeInfluenza A Virus, H3N2 SubtypeMadin Darby Canine Kidney CellsMiceMice, Inbred BALB CMicrobial Sensitivity TestsAntiviral AgentsEnzyme InhibitorsHemagglutinins, ViralNeuraminidaseOseltamivirRecombinant ProteinsViral Proteins

Identifiers

PMID25114143
PMCPMC4249448
OpenAlexW2096737089

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.